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Abstract
Background To report acute and late toxicity with long-
term follow-up, and to describe our experiences with pul-
monary dose constraints.
Methods Between 2002 and 2009, 150 patients with 155
histologically/cytologically proven non-small cell lung can-
cer (NSCLC; tumor stages II, IIIA, IIIB in 6, 55 and 39%,
respectively) received the following median doses: primary
tumors 79.2 Gy (range 72.0–90.0 Gy), lymph node metas-
tases 59.4 Gy (54.0–73.8 Gy), nodes electively 45 Gy; with
fractional doses of 1.8 Gy twice daily (bid). In all, 86% of
patients received 2 cycles of chemotherapy previously.
Results Five treatment-related deaths occurred: pneumoni-
tis, n = 1; progressive pulmonary fibrosis in patients with
pre-existing pulmonary fibrosis, n = 2; haemorrhage, n = 2.
In all, 8% of patients experienced grade 3 and 1.3% grade 4
pneumonitis; 11% showed late fibrotic alterations grade 2
in lung parenchyma. Clinically relevant acute esophagitis
(grade 2 and 3) was seen in 33.3% of patients, 2 patients de-
veloped late esophageal stenosis (G3). Patients with upper
lobe, middle lobe and central lower lobe tumours (n = 130)
were treated with V20 (total lung) up to 50% and patients
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with peripheral lower lobe tumours (n = 14, basal lateral
tumours excluded) up to 42%, without observing acute or
late pulmonary toxicity >grade 3. Only patients with basal
lateral lower lobe tumours (n = 5) experienced grade 4/5
pulmonary toxicity; V20 for this latter group ranged be-
tween 30 and 53%. The mean lung dose was below the
QUANTEC recommendation of 20–23 Gy in all patients.
The median follow-up time of all patients is 26.3 months
(range 2.9–149.4) and of patients alive 80.2 months (range
63.9–149.4.). The median overall survival time of all pa-
tients is 26.3 months; the 2-, 5- and 8-year survival rates of
54, 21 and 15%, respectively. The local tumour control rate
at 2 and 5 years is 70 and 64%, the regional control rate 90
and 88%, respectively.
Discussion and conclusion Grade 4 or 5 toxicity occurred
in 7/150 patients (4.7%), which can be partially avoided
in the future (e.g. by excluding patients with pre-exist-
ing pulmonary fibrosis). Tolerance and oncologic outcome
compare favourably to concomitant chemoradiation also in
long-term follow-up.
Keywords Non-small-cell lung cancer · Dose-
Differentiated Accelerated Radiation Therapy ·
Pneumonitis · Chemotherapy · Pulmonary fibrosis
DART-bid für lokal fortgeschrittene NSCLC
Zusammenfassung der akuten und späten Toxizität mit
Langzeitbeobachtung; Erfahrungen mit pulmonalen Dosis-
schranken
Zusammenfassung
Hintergrund Das Ziel ist die Analyse von akuter und chro-
nischer Toxizität bei Langzeitnachsorge; sowie die Darstel-
lung unserer Erfahrungen mit pulmonalen Dosisschranken.
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Methoden Zwischen 2002 und 2009 wurden 150 Patienten
mit 155 histologisch/zytologisch nachgewiesenem NSCLC
(6% Stadium II, 55% IIIA, 39% IIIB) mit folgenden Medi-
andosen behandelt: Primärtumor 79,2 Gy (72,0–90,0 Gy),
Lymphknotenmetastasen 59,4 Gy (54,0–73,8 Gy), elekti-
ver Lymphabfluss 45 Gy; Einzeldosis 1,8 Gy 2-mal täglich.
86% der Patienten erhielten zuvor 2 Zyklen Chemothera-
pie.
Ergebnisse Fünf Fälle von letalen Nebenwirkungen traten
auf: Pneumonitis (1), progrediente pulmonaler Fibrose bei
bereits prätherapeutisch bestehender pulmonaler Fibrose (2)
und Hämorrhagie (2). Pneumonitiden Grad 3 und 4 wurden
bei 8% und 1,3% der Patienten beobachtet. 11% zeigten
einen späten pulmonalen fibrotischen Umbau Grad 2. Eine
klinisch relevante akute Ösophagitis (Grad 2 und 3) wurde
bei 33,3% Patienten beobachtet, 2 Patienten entwickelten
eine chronische Ösophagusstenose (Grad 3). Patienten mit
Tumoren in Ober-, Mittel- und zentralen Unterlappen (n =
130) wurden mit V20 (Gesamtlunge) bis 50% und Patien-
ten mit peripheren Unterlappentumoren (n = 14, ohne basal-
laterale Tumoren) bis 42% behandelt, ohne dass Pneumo-
nitiden >Grad 3 aufgetreten wären. Nur Patienten mit basal-
lateralen Unterlappentumoren (n = 5) entwickelten Pneu-
monitiden Grad 4/5; die V20 (Gesamtlunge) für diese Pati-
enten lag zwischen 30 und 53%. Die mittlere Lungendosis
(MLD) lag für alle Patienten unterhalb der von QUANTEC
empfohlenen Werte von 20–23 Gy. Die mediane Nachbe-
obachtungszeit aller Patienten betrug 26,3 Monate (Range:
2,9–149,4) und die der lebenden Patienten 82,2 Monate
(Range: 63,9–149,4). Die mediane Gesamtüberlebenszeit
aller Patienten betrug 26,3 Monate, die 2-, 5- und 8-Jahres-
Überlebensraten lagen bei 54, 21 bzw. 15%. Die lokale Tu-
morkontrollrate nach 2 und 5 Jahren betrug 70 bzw. 64%,
die regionale Kontrollrate 90 bzw. 88%.
Diskussion und Schlussfolgerung Insgesamt 7/150 (4,7%)
Patienten zeigten eine Toxizität Grad 4/5, die in Zukunft
teilweise vermieden werden kann (z.B. durch Exklusion
von Patienten mit präexistenter Pulmonalfibrose). Abgese-
hen davon erscheinen Toleranz und klinische Ergebnisse
auch im Langzeitverlauf vorteilhaft gegenüber konkomi-
tanter Chemoradiotherapie.
Schlüsselwörter Nichtkleinzelliges Bronchialkarzinom ·
Dosisdifferenzierte akzelerierte Radiotherapie ·
Pneumonitis · Chemotherapie · Lungenfibrose
Introduction
In all, 30–35% of non-small-cell lung cancer (NSCLC)
patients are initially diagnosed with locoregionally ad-
vanced disease. Radiotherapy, often in combination with
chemotherapy, is the cornerstone of treatments for these
patients. The ability to apply effective radiation doses is,
as in all patients and all tumour sites, limited by the tol-
erability of normal tissues. Before volumetric arc therapy
(VMAT) techniques became widely available, the method
of target splitting was a decisive step towards higher dose
delivery than was possible with standard three-dimensional
(3D) conformal techniques [1].
We used target splitting for treating patients with nonre-
sected NSCLC in stages II–IIIB in accelerated fractionation
(termed DART-bid [dose-Differentiated Accelerated Radi-
ation Therapy, 1.8 Gy twice daily]) and reported the results
of a phase I/II trial and a consecutive prospective study with
minimum follow-up times of 2 years [2, 3].
In this article, acute as well late toxicity at long-term
follow-up (minimum 5 years) of all patients are critically
re-assessed and summarized. In addition, our experience
regarding pulmonary constraints with this novel approach
is described. Figures for survival and tumour control are
also updated.
Methods
Between 2002 and 2009, 183 consecutive patients diag-
nosed with locally advanced lung cancer (stages II/III) were
referred to our department. Patients with Pancoast tumours
(n = 7), lack of curative possibility (n = 11) and poten-
tially curable patients in very poor general condition (n =
15) were excluded from the present analysis (Table 1). The
remaining 150 patients form the study population of this re-
port, which comprises three subcohorts: 23 patients of a pi-
lot study in 2002/2003 having received 84.6 Gy (mean dose)
to the primary tumours and 63 Gy to nodes, respectively
[2]; 123 patients, enrolled in a prospective trial between
2004 and 2009, where primary tumours were treated with
increasing doses in 4 bins (73.8 Gy–90.0 Gy) depending on
tumour size [3], and 4 patients treated in analogous mode in
the time between these two studies (Table 1 and 2). Hence,
the total cohort represents the clinical reality at a tertiary
referral centre unlike patient selections frequently observed
in randomized phase III trials.
Patient and tumour characteristics
Patient and tumour characteristics are listed in Table 2. Pa-
tients were staged according to the TNM system 6th edition.
Of note, 26% of patients had the prognostic unfavourable
feature of weight loss >5% and 43% a Karnofsky Index
70%. A total of 70% of patients were PET-CT staged.
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Table 1 Overview of all referred NSCLC patients in stages II and III
within the study periods
A. DART-bid doses not applicable for constraints plexus
brachialis
Pancoast tumours 7







































D. Patients included in the studies 150
DART-bid dose-differentiated accelerated radiation therapy, 1.8 Gy
twice daily, NSCLC non-small-cell lung cancer
Radiotherapy
Treatment parameters are depicted in Table 3. Notably, in-
volved nodes were treated with lower doses than primary
tumours. Treatments were applied in two daily fractions of
1.8 Gy (ICRU specification) in a median of 32 days.
Planning CTs were performed as “slow CTs”, with
patients freely breathing or as 4D-CT/average projection
(internal target volume concept). A planning CT in treat-
ment position from the apex to the bases of the lung and
dose–volume parameters is available in 72 patients for
whom dose–volume histograms (DVHs) were generated
as usual. In 57 patients with incomplete CT datasets of
the total lung extension (dating mainly before 2005), V20
was assessed by geometric approximations. In 20 patients
(13%), dose–volume parameters are not available, mostly
because parts of the lower lungs were not depicted. Hence,





























Squamous cell carcinoma 97 (62)
Adenocarcinoma 40 (26)






NSC – n.o.s. Non small cell – not otherwise specified, AJCC American
Joint Commission on Cancer, FDG-PET 18-fluorodeoxyglucose-
positron emission tomography, ccm cubic centimeter
dosimetric results refer to the 72/150 (48%) of the patients
with computer-based DVHs. In contouring the lungs as
organs at risk, the gross tumour volume (GTV) is excluded
from the lung volume. Tissue inhomogeneities were taken
into account by a pencil beam algorithm. Mostly the con-
formal target splitting technique was used, details have
been described previously [3]. In patients with computer-
based V20 assessment, the median value for both lungs
(volume receiving ≥20 Gy) was 32% (range 13–53%), for
the ipsilateral lung 43% (range 18–69%) and for the con-
tralateral lung 20% (range 0–39%). A dose constraint for
spinal cord was set at 45 Gy and for oesophagus at 80 Gy
(measured in the centre of the oesophagus at its most ex-
posed level). KV-based IGRT was performed by matching
central anatomical structures such as oesophagus, trachea,
main bronchi [4].
Medicinal agents
In 129 of 150 patients (86%), 2 cycles of chemotherapy
were administered prior to radiotherapy, in general cisplatin
or carboplatin containing doublets. We sought to keep the
interval between chemotherapy and radiotherapy <8 days.
If parts of the oesophagus were within or near the plan-
ning target volume (PTV), an antimycotic prophylaxis was
given (amphotericine B lozenges, 4 times daily, during the
K
318 Strahlenther Onkol (2017) 193:315–323
Table 3 Treatment characteris-
tics (150 patients, 155 tumours) Total dose (Gy) Primary tumour (median, range) 79.2 (72.0–90.0)
Nodes (median, range) 59.4 (54.0–73.8)
Nodes electivelya (in 87% of
patients)
45.0
Fractional dose (Gy) 1.8 bid
Interval ≥10 h






Cycles (n, range) 2 (1–10)
aTo sites about 6 cm cranial to macroscopically involved nodes
bid twice daily
full course of radiotherapy). In 2002, 14 patients of the
phase I/II trial received a prophylactic treatment for pneu-
monitis by inhalative budesonide (0.4 mg twice daily by
turbohaler) routinely, starting at week 3 after radiation for
a 6-week duration. Similarly, 9 patients in the following pe-
riod received a prophylaxis by daily oral 25 mg prednisone,
at the discretion of the treating physician for patients pre-
sumably being at risk for pneumonitis. With increasing ex-
perience, this practice was changed towards prescription of
steroid therapy only if patients showed clinical symptoms
or radiologic signs.
Follow-up procedures
Patients were seen for assessment of toxicity and tumour
control 6 and 12 weeks after the end of radiotherapy, then
every 3 months for the first year, every 4 months during the
second and third year, and every 6 months thereafter. At
the first follow-up a chest X-ray, at all other controls tho-
racic CT scans were performed. Local or regional tumour
progression was diagnosed if there was an increase in tu-
mour volume compared with the previous CT scan. In case
of doubt, a FDG-PET CT was performed. Acute and late
toxicity was scored according to the RTOG/EORTC criteria
except for pulmonary toxicity grade 1, because the criterion
“mild symptoms of dry cough or dyspnoea on exertion” is
common in these pulmonarily compromised patients. Pul-
monary toxicity is considered late if persistent or developed
beyond 6 months after the completion of radiotherapy. For
the purpose of this report, the records, treatment plans and
all pre- and posttherapeutic radiologic material (CT and
PET-CT scans, thoracic X rays) of all patients were exam-
ined. Based on our experience with high-dose accelerated
radiotherapy accumulated in 15 years, we critically re-as-
sessed initial toxicity scorings and corrected these in some
cases.
Statistical analysis
Overall survival and local tumour control rates were cal-
culated using the Kaplan–Meier method. All time intervals
refer to the start of therapy. One patient was lost to follow-
up for emigration, but was disease-free at 26.4 months and
censored at that point of time.
Results
Results of 150 patients treated for 155 histologically/
cytologically proven tumours are reported. The median
follow-up time for all patients is 26.3 months (range
2.9–149.4 months), for survivors 80.2 months (range
63.9–149.4 months). At the time of this analysis, 20 patients
are alive (19 of them disease-free, one with bone metas-
tases); 49/31/12 patients were observed >3/>5/>8 years,
respectively.
Toxicity
Acute and chronic toxicity for lung, oesophagus and vessels
are summarized in Table 4.
Oesophagus
A clinically relevant acute oesophagitis (i. e. > grade 1) was
seen in 50/150 (33.3%) patients: 31/150 (20.7%) grade 2
and 19/150 (12.8%) grade 3, respectively. In all of these pa-
tients, the symptoms ceased within 3 months. These figures
are in line with a previous report on a subset of these pa-
tients [5]. Two patients developed late oesophageal toxicity
grade 3 (stenosis), both received a stent 7 and 10 months
after the end of radiotherapy, respectively.
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Table 4 Acute (A) and late (B) nonhaematologic toxicity according to EORTC/RTOG criteria, n (%)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
A Oesophagus n.a. 31(20.7) 19 (12.8) – –
Pneumonitis n.a. 3 (2) 12 (8) 2 (1.3) 1 (0.7)
Progression of pre-ex-
isting fibrosis
– – – – 2 (1.3)
B Oesophagus – – 2 (1.3) – –
Lung n.a. 16 (11) – – –
Haemorrhage – – – – 2 (1.3)
EORTC/RTOG European Organisation for Research and Treatment of Cancer/Radiation Therapy Oncology Group., n.a. not assessed
Fig. 1 The figure shows the subdivision of the peripheral lower lobes
into four parts; 1 = diaphragm; shaded: basal lateral part, which was
the primary tumour site in patients with pneumonitis grades 4 and 5.
a-p anteroposterior, lat. lateral
Pneumonitis
An acute pneumonitis grade 2, 3, 4 and 5 occurred in 3, 12,
2 and 1 patient, respectively, corresponding to 2, 8, 1.3 and
0.7% of all cases.
The primary tumours of 12 patients scored grade 3 were
situated in the upper, middle and lower lobes in 4, 1 and
7 patients, respectively. Ten of them showed clinical symp-
toms grade 1 or 2 only; however since they were treated
by steroids, they have been scored grade 3 by definition
of the RTOG-EORTC system (“steroids may be required”).
Only one patient showed in fact clinical grade 3 symptoms
(dyspnoea at rest), which was possibly also attributable to
a reactivated tuberculosis and/or a local recurrence. An-
other patient was supported by oxygen before the treat-
ment, improved by radiation first but returned to oxygen
support after a local posttherapeutic reaction. Of note, the
outcome of patients scored G3 (n = 12) was not compro-
mised in terms of survival: median survival 38.3 months
(range 11.9–112.6 months) versus 26.3 months of the whole
cohort. Four of these patients are alive at a median time of
77.4 months (range 68.6–112.6 months).
In 2 patients, a grade 4 and in 1 patient a grade 5 pneu-
monitis occurred. The primary tumours of these 3 patients
were exclusively located in the basal, lateral parts of the
lower lobes (Fig. 1). The grade 5 patient had a 4 cm tu-
mour and extended mediastinal and hilar nodes; the V20
of his treatment was 53%. Six weeks post-RT the patient
died with bilateral pulmonary infiltrates. One patient scored
G4, also with extended nodal involvement, received a V20
of 51%; 10 weeks posttherapy a pneumonitic infiltrate first
improved with steroids but returned 2 months later. Six
weeks later she died due to a central, bilateral pulmonal em-
bolism in combination with hepatic, pleural and pulmonary
metastases. Another patient scored grade 4 was affected by
a 2.5 cm primary tumour and subcarineal and hilar nodes
only, but presented in reduced performance status. There-
fore, elective nodal irradiation was not performed, and the
resulting V20 was 30%. Seven weeks post-RT an infiltrate
of the ipsilateral lower lobe occurred and signs of cardiac
failure; the patient died within 6 days.
Regarding late toxicity, almost all patients showed lo-
cal radiologic alterations of the lung parenchyma, which
were scored grade 2 in 11% of the patients. Usually after
9–12 months (at the latest after 18 months), fibrotic trans-
formations in all patients were consolidated, and no further
alterations were observed thereafter.
Pre-existing pulmonary fibrosis
Two patients with pre-existing pulmonary fibrosis died for
a grade 5 toxicity: progressive pulmonary fibrosis 5 and
6 months after the end of radiotherapy and were therefore
not classified as pneumonitis. These patients were treated
with high pulmonary doses, which did however not exceed
the usual institutional ranges (V20 of 43 and 37%, respec-
tively). Henceforward, and as a consequence, patients with
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pulmonary fibrosis were excluded from high-dose DART-
bid treatments.
Pulmonary haemorrhages
In 2 patients scored grade 5, a treatment-related cause can-
not be excluded. One patient, treated with 79.2 Gy for a cen-
tral tumour of 4 cm with close proximity to the bronchial
arteries died 6.5 months after finishing radiotherapy. The
autopsy demonstrated a leakage of a bronchial artery with-
out detection of recurrent tumour nor necrotic tissue. An-
other patient was treated with 88.2 Gy for a 9 cm tumour
of the peripheral upper lobe with a 6 cm central necrotic
cavity. The patient died due to a massive haemorrhage
4 months after therapy, possibly also caused by a cavity
progression; however, since an autopsy was not performed,
radiation damage cannot be excluded. In 2 further patients
recurring central tumours were diagnosed prior to lethal
haemorrhage; these were not classified as toxic events.
Central tumours
A total of 21 patients with central tumours were treated
with doses ≥82.8 Gy (median 84.6 Gy, range 82.8–87.3 Gy);
main bronchi, lobar bronchi and sometimes also parts of
the trachea lay completely or partially in the high-dose vol-
ume. Usually some narrowing of the bronchial lumen can
be seen, which in some cases lead to segmental or lobar
atelectasis, but alterations as cartilaginous necrosis or sim-
ilar were not observed (and also no lethal haemorrhages in
these patients).
Secondary malignancies
During the follow-up period, in 11 patients twelve second
lung cancers were diagnosed at a median of 24 months
(range 10–62 months); four of them in the contralateral
lung, five in another lobe, three in the same lobe but clearly
distant from the initial primary lesion. NSCLC, SCLC and
PET positive nodules without morphologic confirmation
were found in 3, 2 and 7 tumours, respectively. Eleven
tumours were treated with another course of radiotherapy
in curative intent. The cumulative incidence of second lung
cancers at 8 years is 19%. In the thoracic region no sec-
ondary malignancies other than lung tumours were ob-
served.
In 8 patients extrathoracic secondary cancers occurred at
44 months (median; range 9–71 months) with primaries in
the head and neck region (n = 4), colon (n = 2), kidney and
urinary bladder (one patient each).
Experience regarding pulmonary dose constraints
Patients with upper lobe, middle lobe and central lower
lobe tumours (n = 130) were treated up to a bilateral V20
of 50%. For the 14 patients with peripheral lower lobe tu-
mours, basal lateral ones excluded, V20 amounted to 42%.
Despite this frequent exceeding of V20 constraints defined
by QUANTEC (V20  30–35%) [6], no cases of severe
pneumonitis were observed. As for mean lung dose (MLD),
the median was 16.3 Gy (range 8.6–22.3 Gy); 88% of the
patients received MLDs <20 Gy, while 12% reached values
between 20 and 23 Gy. Notably, and in contrast to the V20
figures, no patient transgressed the QUANTEC recommen-
dation of MLD <20–23 Gy.
With regard to basal lateral lower lobe tumours how-
ever, 3 patients who received V20s of 53, 51 and 30% re-
spectively, experienced grade 4/5 pneumonitis as described,
whereas 2 patients with V20s of 40 and 33%, respectively,
did not.
Survival, locoregional tumour control
The median overall survival time of all patients is 26.3
months; the 2-, 5- and 8-year survival rates were 54, 21 and
15%, respectively. The 5-year survival rate for patients in
stage II, IIIA and IIIB is 22%, 28% and 12%, respectively.
We observed 40 local recurrences, in 90% within 2 years,
resulting in a local tumour control rate at 2 and 5 years of
70 and 64%. In all, 13 patients showed an isolated regional
failure, corresponding to a regional control rate of 90 and
88% at 2 and 5 years, respectively.
Discussion
This is a summary report on acute and late toxicity of
150 widely unselected NSCLC patients in stages II–IIIB
with long-term follow-up.
Oesophagus
Compared to concurrent chemoradiation regimens, where
acute esophagitis ≥ grade 2 is described in up to 44% [7],
the incidence rate in our patient cohort is slightly lower
(33.3%). In fact, the maximum dose constraint of 80 Gy
measured in the centre of the oesophagus at its most ex-
posed level was transgressed only by 2 patients, and only
4 patients had a mean oesophageal dose above the 34 Gy
recommended by QUANTEC [8].
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Topography of peripheral lower lobe tumours
As grade 4/5 pneumonitis arose only in patients with pe-
ripheral lower lobe tumors, the topography of these tumors
was studied more intensely. The lower lobes, as presented
in the CT scans (lung window) of the PET-CT scans, were
subdivided into four parts: basal lateral, basal medial, non-
basal lateral, nonbasal medial (Fig. 1). A primary tumour
was classified as “basal” if it was completely or partially
depicted caudally of the apex of the diaphragm, and it was
classified “lateral” or “medial” if the centre of the tumour
was located within the lateral or medial half of the lobe. A
total of 19 peripheral (and 18 central) lower lobe tumours
were treated, distributed within the four above mentioned
areas in 5, 5, 4 and 5 cases, respectively.
Evolvement of pulmonary dose constraints
The result of three of 150 (2%) patients with grade 4/5
pneumonitis and 12/150 (8%) patients with grade 3 pneu-
monitis and advantageous outcome as described seems to
be a reasonable result. For modern chemoradiation sched-
ules, pulmonary toxicities grade ≥3 up to 10% are reported
[7, 9–11]. According to the RTOG 0617 protocol V20 to-
tal lung was <37%. The other aforementioned studies do
not explicitly state pulmonary dose constraints. In a pooled
analysis of 800 patients, fatal pneumonitis occurred in 1.9%
[12].
Initially in the 1990s, we respected the constraints for 3D
conformal therapies prevailing at that period: bilateral V25
30% and V20 (single lung) 50% [13–15]. As we observed
that treatments were well tolerated and did not even cause
low-grade toxicity, we successively – if necessary – sur-
passed the initial level of the constraints in about a third of
the total patient cohort. In the present analysis patients with
upper, middle and central lower lobe tumors were treated
with V20s up to 50% and peripheral lower lobe tumours
(basal lateral ones excluded) up to 42%.
A precondition to keep toxicity low is the adherence
to the following “rules”: apart from sequential chemora-
diotherapy and tight PTV margins, we believe that a key
issue lies in the minimization of dose to the ipsilateral lung
and accordingly appropriate beam arrangements, also at the
cost of the uninvolved contralateral lung. Constraints are
frequently driven by the level of e. g. bilateral V20, caus-
ing symptomatic pneumonitis. In “contralateral lung dose
sparing” approaches (as usually advocated), pneumonitis
will arise at a relatively low target dose although V20 total
lung is kept low. In contrast, “ipsilateral lung dose spar-
ing” approaches (thus also “allowing” irradiation of the
contralateral lung) will result in a higher target dose and
most probably also in a higher V20 total lung as the pu-
tatively constraint determining value. Thus, a constraint is
not an absolute figure, which must not be surpassed, but
also depends on the technical approach. Interestingly, the
MLDs of our patients were within the limits of 20–23 Gy
recommended by QUANTEC [6].
The considerations of the QUANTEC report are based
on conformal 3D planned therapies with conventional frac-
tionation [6]. It proposes to limit V20 to 30–35% (MLD
20–23 Gy) in order to limit the risk of symptomatic pneu-
monitis to 20%. It states that the significance of dosimet-
ric parameters is technique dependent and that many non-
DVH-based factors, such as performance status, age and
comorbidities, may affect the risk of pneumonitis. This is
in line with our own experience.
On the other hand, respecting published constraints is no
guarantee to be “on the safe side”. Apart from the above
mentioned aspects, tumour topography seems to play a rele-
vant role: The fact that the primary tumours of our grade 4/5
patients were located exclusively in the basal lateral part of
the lower lobes is not entirely surprising. Patients with this
lung cancer topography (plus N2/3 nodes) are at risk for
extraordinarily high radiation exposure because great parts
of the posterior sulcus and the lower parts of the lower lobe
are irradiated. Applying classical constraints might be too
high in these lung regions.
Interestingly, the 2 patients with basal lateral lower lobe
tumours without pneumonitis presented with chronic ob-
structive pulmonary disease (COPD) grade 3 and 4; and
the patient with COPD grade 4 is still alive and disease-
free after 7.5 years. Seemingly high-grade COPD is not an
obstacle for high-dose radiation treatment, at least if the
tumour load is not too extended. From surgical literature
it is well established that COPD patients may experience
improvement of pulmonary function after thoracic surgery
because of amelioration of respiratory mechanics by re-
moval of nonfunctional tissue [16]. Thus, high-dose irradi-
ation could have an effect similar to surgical lung volume
reduction.
On the other hand, the risk of radiation induced lung
injury may depend on tumour location. As stated e. g. in
a meta-analysis by Vogelius mid or inferior lung tumours
are associated with a higher risk of radiation pneumonitis
[17]. This may reflect higher mechanical stress in the alveoli
of the mid and lower lobes compared to other parts of the
lungs. A different explanation could be a relatively higher
proportion of irradiated normal lung tissue due to increased
organ motion in the lower parts of the lung.
Late sequelae
In almost all patients local fibrotic transformations of the
lung parenchyma can be observed which however only in
11% reached dimensions to be scored grade 2. Notably, in
central tumours, hilar structures could be treated with me-
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dian doses of 85 Gy in two daily fractions of 1.8 Gy without
causing essential toxicity. There is no evidence of malig-
nancy induced by radiation. No thoracic second tumours
other than secondary lung cancers occurred. The cumula-
tive incidence of secondary lung cancers at 8 years in our
cohort is 19%, which is in line with the reported 2–3%
annual risk following surgery of lung cancer [18, 19].
Comparison to results of other approaches
At present concurrent chemoradiotherapy is regarded as the
best treatment option for patients concerned. However, for
reasons of toxicity this modality is only amenable for about
30% of the patients [11]. In addition, the possibilities to im-
prove results by dose escalation seem to be strongly com-
promised by the negative outcome of RTOG 0617, show-
ing worse results applying 74 Gy instead of 60 Gy simul-
taneously to chemotherapy [7]. It seems that concurrent
chemotherapy hampers the full potential of more intense
radiotherapy; this drawback is overcome by the sequential
modality of DART-bid.
Median overall survival in concurrent therapies is re-
ported between 17 and 28.7 months [7, 11, 20]. The good
result of 28.7 months in RTOG 0617 might be influenced
by the strict exclusion criteria regarding comorbidities [7].
As discussed in a recently published article, assessment
and reporting of local tumour control is complex; concur-
rent chemoradiotherapies were reported to achieve defini-
tive local tumour control rates of up to 65% at 2 years
in positively selected patient populations [7]. In a widely
unselected clinically representative patient population we
reached a median overall survival of 26.3 months and local
and regional tumour control rates of 70 and 90% at 2 years,
respectively.
Limitations
Doses and dose–volume relationships in our patients were
calculated with pencil beam algorithm. Nowadays mostly
type B algorithms (e. g. collapsed cone) are used, which
compute doses more accurately, especially in sites with
heterogeneous tissues as in the thorax [21]. In a subset
of 19 patients in our cohort the relative median decrease
in V20 was 4% between pencil beam and collapsed cone.
This means that a V20 of 30% (pencil beam) corresponds
to 28.8% (collapsed cone). As of 2010, collapsed cone was
used at our institution without changing prescription doses.
Although we did not assess this systematically, differences
in treatment tolerability were not observed.
It is a general weakness of the current study that for only
half of the patients computer-based dose–volume histogram
calculations are available. Therefore, reported figures con-
cerning pulmonary constraints only refer to these patients.
Conclusion
With the concept of high-dose DART-bid excellent locore-
gional tumour control rates are achievable, while producing
acceptable toxicity also in long-term follow-up. This is pri-
marily due to the following aspects:
● Ipsilateral lung radiation exposure is not maximally ex-
hausted, at the cost of contralateral exposure. This is
however better tolerated than usually expected with the
benefit of higher target doses and subsequently high local
control rates. In this respect, the target splitting treatment
concept anticipated dose distribution models becoming
more and more routine in times of intensity-modulated
radiotherapy.
● Compared to traditional target concepts, relevant parts of
the ipsilateral lung remain spared due to tight margins.
In our approach, higher doses are only administered to
small volumes.
● Nodal metastases are treated with lower doses than pri-
mary tumours.
● Chemotherapy is administered in a sequential instead of
a concurrent mode. Thus, and unlike many concurrent
chemoradiation schemes, this approach is feasible for the
vast majority of lung cancer patients with locoregionally
advanced stages.
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